THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND

被引：1
|
作者：
Kolasa, K. [1 ]
Niewada, M. [2 ]
de Troconiz, J. Puelles Fernandez [3 ]
Townsend, R. [4 ]
McEwan, P. [4 ]
机构：
[1] Bristol Myers Squibb, Warsaw, Poland
[2] HealthQuest Sp Oo, Warsaw, Poland
[3] Bristol Myers Squibb, Braine Lalleud, Belgium
[4] CRC, Cardiff, S Glam, Wales
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72095-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A290 / A290
页数：1
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [2] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [3] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [4] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [5] The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland
    Grzeszczak, Wladyslaw
    Czupryniak, Leszek
    Kolasa, Katarzyna
    Sciborski, Cezary
    Lomon, Isabelle Duprat
    McEwan, Phil
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (01) : 65 - 73
  • [6] COST-EFFECTIVENESS OF INSULIN DETEMIR IN T2DM PATIENTS POORLY CONTROLLED WITH NPH INSULIN IN POLAND
    Kaczor, M. P.
    Pawlik, D.
    Wojcik, R.
    Jurkiewicz, B.
    VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
  • [7] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in the Canadian payer setting
    Kapor, Jovana
    Minshall, Michael E.
    Tunis, Sandra L.
    Conner, Chris
    Mccormick, John
    Seager, Christine
    Groleau, Danielle
    DIABETES, 2008, 57 : A98 - A98
  • [8] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
  • [9] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [10] Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: Modeling analysis using an observational study
    Minshall, M. E.
    Tunis, S. L.
    Conner, C.
    McCormick, J., I
    Kapor, J.
    Groleau, D.
    VALUE IN HEALTH, 2008, 11 (03) : A224 - A224
12345